ISA Pharmaceuticals B.V. is a biopharmaceutical company developing rationally designed, fully synthetic therapeutic vaccines against cancer and persistent viral infections. The company's vaccine platform is based on its proprietary synthetic long peptide (SLP^®) and AMPLIVANT^™ technologies that allow for the generation of safe and effective vaccines with a well-defined mechanism of action. These vaccines are designed to activate the natural immune system and are broadly applicable to a multitude of targets and can be used as monotherapy and in combination with standard cancer treatments.

The company was founded in 2004 by Aglaia Oncology Fund and is based in Leiden, the Netherlands.